Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma

Inclusion Criteria:

• Histological diagnosis of thoracic Esophageal squamous cell carcinoma
• ECOG performance status 0-1
• Age 18-75 years
• Resectable disease, cT2-4aNanyM0 or cT1-3N+M0
• Life expectancy more than 6 months
• Use of an effective contraceptive for adults to prevent pregnancy

Exclusion Criteria:

• Not suitable for surgery
• Prior chemotherapy, radiotherapy and immune-oncology therapies for ESCC
• Prior esophageal, gastric, or gastro-esophageal junction surgery
• Esophageal ulcer, esophageal perforation，chest pain（≥middle level）
• Pregnant or lactating women